Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases

BACKGROUND: Osimertinib is a selective irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) with increased penetration across the blood–brain barrier compared with previous EGFR-TKIs, and thus, a 52% reduction in the risk of intracranial disease progression is seen when...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldstein, Iris M, Roisman, Laila C, Keren-Rosenberg, Shoshana, Dudnik, Julia, Nechushtan, Hovav, Shelef, Ilan, Fuchs, Vered, Kian, Waleed, Peled, Nir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648590/
https://www.ncbi.nlm.nih.gov/pubmed/33196042
http://dx.doi.org/10.1093/noajnl/vdaa125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648590/
https://www.ncbi.nlm.nih.gov/pubmed/33196042
http://dx.doi.org/10.1093/noajnl/vdaa125

Ejemplares similares